ADvantage Therapeutics
Cambridge, United States· Est. 1991
We are developing a novel immunotherapy for early AD.
Private Company
Total funding raised: $28.9M
About
We are developing a novel immunotherapy for early AD.
Small Molecules
Funding History
22Total raised:$28.9M
Seed$15MJun 15, 2023
Grant$611KMar 3, 2021
Grant$611KJan 31, 2020
Grant$116KSep 13, 2019